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An enzyme immunoassay kit that detects serum IgA antibody reacting to glycopeptidolipid core antigen derived fromMycobac-
terium avium complex (MAC) was not useful for differentiating MAC pulmonary disease (PD) fromMycobacterium abscessus
complex PD (MAB-PD). However, this assay could be useful for differentiatingMAC- andMAB-PD from pulmonary tuberculo-
sis. (This study has been registered at ClinicalTrials.gov under registration no. NCT00970801.)
An enzyme immunoassay (EIA) that detects serum immuno-globulin A (IgA) antibody reacting to the glycopeptidolipid
(GPL) core antigen of Mycobacterium avium complex (MAC) was
developed (1). This EIA kit was useful for rapid diagnosis of MAC
pulmonary disease (MAC-PD) and for differentiating MAC-PD
from pulmonary tuberculosis (PTB) (1–5).
MAC, followed byMycobacteriumabscessus complex (MAB), is
the most common etiologic organism in PD caused by nontuber-
culous mycobacteria (NTM-PD) in many countries, including the
United States and South Korea (6–9). Because MAB also possesses
GPL on its cell surface (10), there is a possibility of false-positive
results in patients with MAB-PD. However, this EIA kit has not
been evaluated in MAB-PD (1–5). The objective of this study was
to evaluate the diagnostic performance of this EIA kit in patients
with NTM-PD caused by MAB as well as by MAC.
Serum samples were collected from patients with NTM-PD
diagnosed between January 2008 and December 2011 at the Sam-
sung Medical Center (a 1,950-bed referral hospital in Seoul, South
Korea). The patients were enrolled in an institutional review
board-approved observational cohort study investigating NTM-PD
(ClinicalTrials.gov identifier NCT00970801). Informed consent was
obtained from all participants. All patients met the diagnostic criteria
for NTM-PD according to the guidelines of the American Thoracic
Society (11).
The study groups included 40 MAC-PD patients (20 M. avium
and 20 M. intracellulare), 40 MAB-PD patients (20 M. abscessus
sensu stricto and 20 M. massiliense), 20 culture-confirmed PTB
patients, and 20 healthy controls. All patients were newly diag-
nosed and had not been treated for NTM lung disease at the time
of collection of the serum samples.
Serum IgA antibodies against the GPL core antigen were mea-
sured using the EIA kit (Tauns Laboratory Inc., Shizuoka, Japan)
according to the manufacturer’s instructions (2, 3). Results are
given as arbitrary U/ml and reported as positive when the IgA titer
was more than 0.7 U/ml (2, 3). The titers of each study group are
presented as medians and interquartile ranges (IQR) and were
compared using the Kruskal-Wallis test with post hoc paired com-
parisons using the Bonferroni method. We estimated the sensitiv-
ity, specificity, and positive predictive value (PPV) and negative
predictive value (NPV) for a preset cutoff point (0.7 U/ml) and
the best cutoff point, which showed the highest Youden index
([sensitivity specificity] 1) (12). The discriminative power of
the EIA kit was assessed by calculating the area under the receiver
operating characteristic curve (AUC). We used STATA ver. 11
(STATA Corp., College Station, TX) for all analyses and consid-
ered a 2-sided P of0.05 to be statistically significant.
The median age was 62 (IQR, 49 to 70) years in the MAC-PD
patient group, 56 (IQR, 48 to 68) years in the MAB-PD patient
group, 60 (IQR, 53 to 67) years in the PTB patient group, and 56
(IQR, 52 to 61) years in the control groups. The proportions of
male patients were 40%, 23%, 75%, and 50% in the MAC-PD,
MAB-PD, PTB, and control groups, respectively. The proportions
of patients with the nodular bronchiectatic form of MAC- and
MAB-PD were 83% and 80%, respectively. None of the subjects
were positive for human immunodeficiency virus infection.
Figure 1A shows a scattergram of IgA antibody titers plotted
against the GPL core antigen in each group. Significantly higher
levels were detected in the MAC-PD group (median, 6.96; IQR,
1.12 to 14.00 U/ml) than in the other groups (P 0.030 for MAB-
PD, P  0.001 for PTB, and P  0.001 for the control group).
However, the MAB-PD group (median, 1.28; IQR, 0.54 to 4.43
U/ml) also had a higher titer than the PTB group (median, 0.09;
IQR, 0.07 to 0.11 U/ml; P  0.001) and controls (median, 0.08;
IQR, 0.07 to 0.10 U/ml;P 0.001). The positivity rates for the EIA
were 85%, 70%, 0%, and 0% in the MAC-PD, MAB-PD, PTB, and
control groups, respectively.
In the study subjects, excluding MAB-PD, the discriminatory
power for detection of MAC-PD was high (AUC, 0.98; 95% con-
fidence interval [CI], 0.95 to 1.00), with 85% sensitivity, 100%
specificity, and 100% PPV at a preset cutoff of 0.7 U/ml, which
were similar to values seen at the best cutoff point (0.69 U/ml)
(Fig. 1B). Among all study subjects, including those with MAB-
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PD, however, the discriminatory power and the PPV for detection
of MAC-PD were weakened to an AUC of 0.83 (95% CI, 0.76 to
0.90), with 85% sensitivity, 65% specificity, and 54.8% PPV at a
preset cutoff value and 72.5% sensitivity, 82.5% specificity, and
67.4% PPV at the best cutoff point (1.70 U/ml) (Fig. 1C). In
terms of distinguishing NTM lung disease (both MAC- and MAB-
PD) from others (PTB and control groups), the AUC was 0.96
(95% CI, 0.92 to 0.99), with 77.5% sensitivity, 100% specificity,
and 100% PPV at a preset cutoff value and 85% sensitivity, 100%
specificity, and 100% PPV at the best cutoff point (0.52 U/ml)
(Fig. 1D).
NTM causes a chronic, slowly progressive pulmonary infection
that resembles PTB. In clinical practice, it is difficult to distinguish
NTM-PD from PTB, because the symptoms and radiographic
findings are often similar. This leads to an incorrect diagnosis or
unnecessary treatment in many patients with NTM-PD (13).
Therefore, serodiagnosis of NTM-PD could be useful for rapid
differentiation of NTM-PD from PTB. Our data revealed that this
EIA kit could be useful for differential serodiagnosis of MAC-PD
and PTB, which is consistent with previous studies (1–5).
We found that the level of serum IgA antibody to the GPL core
antigen was higher in both MAB- and MAC-PD patients. In fact,
FIG1 Comparison of the IgA antibody response to glycopeptidolipid (GPL) core antigen and the sensitivity of the enzyme immunoassay. (A) Scattergram of IgA
antibody titers plotted against GPL core antigen from 40 patients with Mycobacterium avium complex pulmonary disease (MAC-PD), 40 patients with M.
abscessus complex pulmonary disease (MAB-PD), 20 patients with pulmonary tuberculosis (PTB), and 20 healthy controls. (B) Receiver operating characteristic
(ROC) curve for detection of MAC-PD in the study subjects, excluding MAB-PD (area under the curve [AUC], 0.98; 95% confidence interval [CI], 0.95 to 1.00).
(C) ROC curve for detection of MAC-PD among all study subjects (AUC, 0.83; 95% CI, 0.76 to 0.90). (D) ROC curve for detection of nontuberculous
mycobacterial lung disease (both MAC- and MAB-PD) among all study subjects (AUC, 0.96; 95% CI, 0.92 to 0.99). PPV, positive predictive value; NPV, negative
predictive value.
Jeong et al.
2748 jcm.asm.org Journal of Clinical Microbiology
 o
n
 M
ay 21, 2014 by YO
NSEI UNIV M
ED LIBRARY
http://jcm.asm.org/
D
ow
nloaded from
 
many NTM organisms, including MAC, MAB, M. fortuitum, M.
chelonae, M. simiae, M. peregrinum, M. senegalense, M. porcinum,
M. smegmatis, andM. butyricum, possess GPL (14, 15). A previous
study from Japan reported that this EIA kit could discriminate
MAC-PD from M. kansasii PD (1). Because GPL is not located on
the surface of the M. kansasii cell wall (16), this finding seems
reasonable. Therefore, this EIA kit is not useful for prediction of
NTM etiology, especially in countries in which MAB is a relatively
common etiology of NTM lung disease.
Antibody titers in our patients with MAC-PD were higher than
those in Caucasian patients (4) and similar to those in Japanese
patients (3, 5). Differences in race, disease status, and etiological
proportion may affect these results and the best cutoff value. Fi-
nally, because of high PPV and low NPV (Fig. 1D), a high value of
serum IgA antibody could be in favor of NTM infection but a low
value could not exclude a possibility of NTM infection.
In summary, this EIA kit that detects serum IgA antibody to the
GPL core antigen cannot differentiate MAC-PD from MAB-PD.
Therefore, caution in the interpretation of the test results should
be required in countries such as the United States and South Korea
in which MAB is a common etiology of NTM lung disease. In
addition, this kit could be useful for differentiating NTM-PD,
including MAC- and MAB-PD, from PTB instead of for differen-
tiating MAC-PD from MAB-PD.
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